StockNews.AI
SNOA
StockNews.AI
195 days

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results

1. Sonoma's revenues grew 14% for the quarter and 13% year-to-date. 2. The company reported positive cash flow with a decline in net loss.

2m saved
Insight
Article

FAQ

Why Bullish?

The revenue increase and positive cash flow may attract investors, similar to past growth. Positive financial metrics often lead to increased stock valuations.

How important is it?

Improving revenues and cash flow significantly impact SNOA's perception and investment potential. Positive trends are critical for a small cap stock's stability and growth.

Why Short Term?

The immediate financial results can influence investor sentiment quickly, as seen historically. Similar quarterly earnings announcements have led to short-term stock price increases.

Related Companies

SNOANASDAQ
Revenues increased 14% for the quarter compared to prior year and 13% year-to-date Positive cash flow from operations for the quarter with $5.2 million of cash at December 31, 2024 Year-to-date net loss decline of $1.1 million BOULDER, CO / ACCESS Newswire / February 5, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its third fiscal quarter and nine months ended December 31, 2024. "We are pleased to report another strong quarter with increased revenues, positive cash flow from operations, and operating expenses remaining flat in an inflationary period," remarked Amy Trombly, CEO of Sonoma.

Related News